PA8849601A1 - Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos - Google Patents

Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos

Info

Publication number
PA8849601A1
PA8849601A1 PA20098849601A PA8849601A PA8849601A1 PA 8849601 A1 PA8849601 A1 PA 8849601A1 PA 20098849601 A PA20098849601 A PA 20098849601A PA 8849601 A PA8849601 A PA 8849601A PA 8849601 A1 PA8849601 A1 PA 8849601A1
Authority
PA
Panama
Prior art keywords
monoclonal antibodies
ferroportina
same
count
reticulocite
Prior art date
Application number
PA20098849601A
Other languages
English (en)
Spanish (es)
Inventor
Doen Mun Leung Donmienne
Luan Peng
Vincent Manetta Joseph
Tang Ying
Ryan Witcher Derrick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PA8849601A1 publication Critical patent/PA8849601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PA20098849601A 2008-12-05 2009-11-23 Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos PA8849601A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12007608P 2008-12-05 2008-12-05
US23981809P 2009-09-04 2009-09-04

Publications (1)

Publication Number Publication Date
PA8849601A1 true PA8849601A1 (es) 2010-07-27

Family

ID=41683589

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098849601A PA8849601A1 (es) 2008-12-05 2009-11-23 Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos

Country Status (25)

Country Link
EP (1) EP2373335B1 (enExample)
JP (1) JP5713917B2 (enExample)
KR (1) KR101353117B1 (enExample)
CN (1) CN102238962B (enExample)
AR (1) AR074398A1 (enExample)
AU (1) AU2009322587B2 (enExample)
BR (1) BRPI0922288A2 (enExample)
CA (1) CA2745618C (enExample)
CY (1) CY1117355T1 (enExample)
DK (1) DK2373335T3 (enExample)
EA (1) EA020472B1 (enExample)
ES (1) ES2566343T3 (enExample)
HR (1) HRP20160302T1 (enExample)
HU (1) HUE028585T2 (enExample)
IL (1) IL212731A0 (enExample)
MX (1) MX2011005939A (enExample)
NZ (1) NZ592545A (enExample)
PA (1) PA8849601A1 (enExample)
PL (1) PL2373335T3 (enExample)
SG (1) SG171960A1 (enExample)
SI (1) SI2373335T1 (enExample)
TW (1) TW201023891A (enExample)
UA (1) UA104741C2 (enExample)
WO (1) WO2010065496A1 (enExample)
ZA (1) ZA201103941B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104284677A (zh) * 2012-05-14 2015-01-14 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
EP3788065B1 (en) 2018-04-30 2025-08-27 The Children's Hospital Of Philadelphia Improving anemias by combining agents
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
CN110806486B (zh) * 2019-11-23 2023-03-21 中南大学湘雅三医院 Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN113980987A (zh) * 2021-12-06 2022-01-28 上海市农业科学院 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) * 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
IT1319221B1 (it) * 2000-10-17 2003-09-26 Antonello Pietrangelo Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria.
CA2711826C (en) * 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use

Also Published As

Publication number Publication date
MX2011005939A (es) 2011-06-27
EP2373335B1 (en) 2016-02-24
JP2012510814A (ja) 2012-05-17
AR074398A1 (es) 2011-01-12
ES2566343T3 (es) 2016-04-12
CN102238962A (zh) 2011-11-09
JP5713917B2 (ja) 2015-05-07
ZA201103941B (en) 2012-11-28
NZ592545A (en) 2012-12-21
AU2009322587B2 (en) 2013-09-26
TW201023891A (en) 2010-07-01
DK2373335T3 (en) 2016-05-02
HRP20160302T1 (hr) 2016-04-22
CN102238962B (zh) 2014-02-12
HK1158977A1 (zh) 2012-07-27
UA104741C2 (uk) 2014-03-11
CA2745618A1 (en) 2010-06-10
BRPI0922288A2 (pt) 2018-08-28
EA020472B1 (ru) 2014-11-28
EP2373335A1 (en) 2011-10-12
CY1117355T1 (el) 2017-04-26
AU2009322587A1 (en) 2011-07-28
SI2373335T1 (sl) 2016-04-29
IL212731A0 (en) 2011-07-31
SG171960A1 (en) 2011-07-28
KR20110084996A (ko) 2011-07-26
WO2010065496A1 (en) 2010-06-10
PL2373335T3 (pl) 2016-08-31
EA201170764A1 (ru) 2011-12-30
CA2745618C (en) 2014-06-10
HUE028585T2 (en) 2016-12-28
KR101353117B1 (ko) 2014-02-17

Similar Documents

Publication Publication Date Title
CY1119743T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
PA8849601A1 (es) Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
DOP2020000032A (es) Proteínas de unión específicas y sus usos
UY33144A (es) Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana
CY1119283T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
UA109633C2 (uk) Антитіло людини проти тканинного фактора
AR073717A1 (es) Anticuerpos anti-notch2 de murino y humano, y metodos de uso
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
EP2595967A4 (en) TETRAZIN TRANS CYCLOOCTS LIGATION FOR FAST CONSTRUCTION OF RADIONUCLIDED TAGS
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
PA8849001A1 (es) Anticuerpos de c-met
GT200900188A (es) Anticuerpos neutralizantes del citomegalovirus humano y su uso.
MX2018016404A (es) Anticuerpos de union a cd3.
MX2019002967A (es) Anticuerpos de union a cd3.
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
ECSP066756A (es) Anticuerpo monoclonal específico m-csf y los usos del mismo
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CO6531481A2 (es) Proteinas de enlace al antigeno il-23 humanas
EA201070518A1 (ru) Композиция по уходу за волосами
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
CL2008003190A1 (es) Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
AR062268A1 (es) Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper